Upstream Processing


AGC Biologics acquires Colorado CGT facility

By Rachel Arthur

CDMO AGC Biologics has acquired a commercial manufacturing facility in Longmont, Colorado: giving it significant additional capacity and space to expand its global end-to-end cell and gene therapy offering.

© GettyImages/Andrew Brookes

Generate looks to in-house stem cell manufacturing

By Jane Byrne

Generate Life Sciences is establishing a GMP facility in La Jolla, California that it says will enable end-to-end manufacturing of newborn stem cell biologics, bolstering supply and safeguarding clinical research.


Sartorius acquires majority stake in CellGenix

By Rachel Arthur

Sartorius is strengthening its product portfolio for cell and gene therapies with the acquisition of a majority stake in German reagent manufacturer CellGenix.

© GettyImages/metamorworks

Gamma Biosiences takes majority stake in Mirus Bio

By Jane Byrne

Gamma Biosciences has taken a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Wisconsin in the US.

© GettyImages/Lars Neumann

KIYATEC flags checkpoint inhibitor response prediction milestone

By Jane Byrne

US company, KIYATEC, says a new study has shown that its immune-modified ex vivo platform can measure treatment response through direct interaction between a patient's cancer and infiltrating immune cells, and immuno-oncology agents.